The government has been shut down since October 1, 2025 due to the inability to come to a bipartisan consensus on how to continue funding the government through October 2025 and beyond. Due to this shutdown, social welfare programs that are controlled by the federal government are subject to delays or even complete closures which could impact benefits of millions of Americans, including young adults with chronic health conditions and/or [...]

Generation Patient seeks a remote (D.C. Metro area preferred) Director of Operations, HR, and Development. The Director of Operations, Human Resources, and Development (Director of Operations) holds a central leadership role at Generation Patient, ensuring that the organization’s infrastructure, systems, and financial management effectively support its mission to advance […]

During times of political disagreement, we stress the importance of bipartisanship to ensure the continued funding of the public programs that are so crucial in supporting young adults living with chronic and rare conditions in America. As patients, we rely on the continued operation of our Federal healthcare agencies to allow for the continued innovation and safety of therapeutics, the continued access to community health centers, the […]

GLP-1 agonist medications like Mounjaro, Wegovy, and Ozempic have exploded with popularity in the past few years. While these medications are not novel, they are now being used for more than type-2 diabetes management. Within the last five years, GLP-1s have gained FDA approval  for weight loss or obesity-management and obstructive sleep apnea, There are also studies into other possible uses for these medications, including for the treatment of […]

Earlier this week, FDA posted numerous warning letters and untitled letters to the manufacturers and telehealth companies for their marketing practices that are harming our young adult patient community. Among these companies targeted were those marketing unapproved compounded GLP-1s, with FDA labeling their products as misbranded. FDA also sent warning letters to manufacturers of approved GLP-1s who have been engaging in […]

Generation Patient welcomes today’s White House announcement of increased oversight and enforcement against deceptive direct-to-consumer (DTC) pharmaceutical advertising on social media platforms.

Have you noticed an increase in medication-related advertisements on your social media? Are the ads targeting your symptoms? Do you feel influenced to buy the medication online?

On June 30th, 2025, our Executive Director, Sneha Dave had the opportunity to represent our young adult patient community at a listening session hosted by the Federal Trade Commission (FTC) and U.S. Department of Justice (DOJ) focused on solutions to lower prescription prices for patients. In the session, Sneha explained to regulators the issues our community faces in accessing pharmaceutical therapeutics, including the 21% of Americans aged […]

Generation Patient, an organization committed to supporting young adults with chronic and rare conditions through community support and policy change, announced its endorsement of Eliminating Thickets to Increase Competition Act (ETHIC Act). Senators Peter Welch (D-VT), Josh Hawley (R-MO), and Amy Klobuchar (D-MN) introduced this bipartisan legislation to address […]

Peer support is a crucial part of our work at Generation Patient. Through our peer support programming, we aim to build community, reduce isolation, and ensure that young adults with chronic conditions have a space to explore their chronic illness identity. We offer eight peer groups per month, spanning three regions of the world, and complement this direct support work with […]

This week, the Trump Administration issued a new Executive Order introducing a “Most Favored Nation” (MFN) policy aimed at reducing prescription drug prices in the United States. The MFN policy seeks to align U.S. drug prices with those paid in other developed countries, where Americans often pay two to three times more for the same medications. The order directs federal […]

Serial patent litigation refers to a branded pharmaceutical company suing a generic pharmaceutical company (i.e., a company that manufactures lower-cost versions of high-cost therapeutics) repeatedly regarding the same generic medication. This process delays the ability to bring generic medications to patients and, in some cases, may completely remove access. […]